Literature DB >> 29936101

Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation.

Helen Cao1, Mark Biondo1, Hadi Lioe1, Samantha Busfield1, Veronika Rayzman1, Bernhard Nieswandt2, Konrad Bork3, Leonard C Harrison4, Priscilla Auyeung4, Henriette Farkas5, Dorottya Csuka5, Matthias Pelzing1, Steve Dower1, Michael J Wilson1, Andrew Nash1, Marc W Nolte6, Con Panousis7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29936101     DOI： 10.1016/j.jaci.2018.06.014

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  7 in total

1.  The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human Trials.

Authors:  Emma P DeLoughery; Sven R Olson; Cristina Puy; Owen J T McCarty; Joseph J Shatzel
Journal:  Semin Thromb Hemost       Date:  2019-06-19       Impact factor: 4.180

2.  Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial.

Authors:  Christina U Lorentz; Norah G Verbout; Michael Wallisch; Matthew W Hagen; Joseph J Shatzel; Sven R Olson; Cristina Puy; Monica T Hinds; Owen J T McCarty; David Gailani; András Gruber; Erik I Tucker
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

Review 3.  FXII: The Cuckoo in the Nest.

Authors:  Roger E G Schutgens
Journal:  Hemasphere       Date:  2018-11-29

4.  A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab.

Authors:  Andrew McKenzie; Anthony Roberts; Sourabh Malandkar; Henrike Feuersenger; Con Panousis; Dipti Pawaskar
Journal:  Clin Transl Sci       Date:  2021-12-03       Impact factor: 4.689

5.  Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312).

Authors:  Dipti Pawaskar; Xi Chen; Fiona Glassman; Frauke May; Anthony Roberts; Mark Biondo; Andrew McKenzie; Marc W Nolte; William J Jusko; Michael Tortorici
Journal:  Clin Transl Sci       Date:  2021-12-08       Impact factor: 4.689

Review 6.  Treatment of hereditary angioedema-single or multiple pathways to the rescue.

Authors:  Anna Valerieva; Hilary J Longhurst
Journal:  Front Allergy       Date:  2022-09-12

Review 7.  The rebirth of the contact pathway: a new therapeutic target.

Authors:  Priyanka Srivastava; David Gailani
Journal:  Curr Opin Hematol       Date:  2020-09       Impact factor: 3.218
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.